Compare FedEx Corporation (FDX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs TransMedics Group Inc — how do they compare? FedEx Corporation trades at $291.66 (market cap $69.04B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: FedEx Corporation is far larger — about 25.2× TransMedics Group Inc's market cap, and FedEx Corporation pays a 1.67% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and TransMedics Group Inc for 24 Days on average.
| FDX | TMDX | |
|---|---|---|
Market Cap | $69.04B | $2.74B |
Volume | 1,287,367 | 949,331 |
Sector | Industrials | Health |
52-Week High | $339.35 | $150.42 |
52-Week Low | $180.87 | $61.99 |
Typical Hold Time | 87 Days | 24 Days |
Enterprise Value | $98.68B | $3.13B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.71, up 0.92% today, with a bearish technical signal but strong fundamentals including a P/E of 15.73 and net income margin of 4.68%. Recent Q1 2026 earnings beat expectations at $6.31 EPS. The company announced a $300 million electric truck order from Harbinger (TechCrunch, 2026-09-30) and a $1.22 dividend payable October 1, 2026. Cash flow from operations was $7.04B in 2025, with a projected rebound to $8.9B in 2026.
The outlook is mixed: analyst consensus is a Buy with a $307.55 price target, but rising fuel costs and geopolitical tensions pose margin risks. Earnings growth and cost-cutting initiatives support upside, while technical resistance near $294 may limit near-term gains. Debt-to-asset ratio is expected to rise to 25.99% in 2026, adding financial leverage concerns.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
